Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Iovance Biotherapeutics, Inc.
LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves participants receiving a non-myeloablative lymphodepletion (NMA-LD) preparative regimen, followed by infusion of autologous TIL, with or without pembrolizumab, followed by the administration of a regimen of IL-2.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted